Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:MASI
- CUSIP: 57479510
- Web: www.masimo.com
Capitalization:- Market Cap: $4.41 billion
- Outstanding Shares: 51,940,000
Average Prices:- 50 Day Moving Avg: $85.78
- 200 Day Moving Avg: $90.95
- 52 Week Range: $53.78 - $104.71
P/E:- Trailing P/E Ratio: 13.92
- Foreward P/E Ratio: 33.46
- P/E Growth: 1.52
Sales & Book Value:- Annual Revenue: $730.06 million
- Price / Sales: 6.05
- Book Value: $13.66 per share
- Price / Book: 6.22
Profitability:- EBIDTA: $182.11 million
- Net Margins: 45.90%
- Return on Equity: 23.45%
- Return on Assets: 16.22%
Debt:- Current Ratio: 3.89%
- Quick Ratio: 3.29%
Misc:- Average Volume: 514,150 shs.
- Beta: 0.84
- Short Ratio: 5.21
Frequently Asked Questions for Masimo Corporation (NASDAQ:MASI)
What is Masimo Corporation's stock symbol?
Masimo Corporation trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo Corporation's earnings last quarter?
Masimo Corporation (NASDAQ:MASI) issued its earnings results on Wednesday, August, 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.71 by $0.12. The business earned $192.90 million during the quarter, compared to analysts' expectations of $189.03 million. Masimo Corporation had a return on equity of 23.45% and a net margin of 45.90%. The business's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.57 EPS. View Masimo Corporation's Earnings History.
When will Masimo Corporation make its next earnings announcement?
What guidance has Masimo Corporation issued on next quarter's earnings?
Masimo Corporation issued an update on its FY17 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of $2.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.60. The company issued revenue guidance of $769 million, compared to the consensus revenue estimate of $759.39 million.
Where is Masimo Corporation's stock going? Where will Masimo Corporation's stock price be in 2017?
7 brokerages have issued 1-year price targets for Masimo Corporation's stock. Their predictions range from $60.00 to $112.00. On average, they anticipate Masimo Corporation's stock price to reach $97.00 in the next year. View Analyst Ratings for Masimo Corporation.
Who are some of Masimo Corporation's key competitors?
Some companies that are related to Masimo Corporation include Alkermes PLC (ALKS), VCA (WOOF), Seattle Genetics (SGEN), WellCare Health Plans (WCG), Steris Plc (STE), Qiagen N.V. (QGEN), ABIOMED (ABMD), Exelixis (EXEL), William Demant Holdings (WILYY), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), TESARO (TSRO), Ionis Pharmaceuticals (IONS), Henry Schein (HSIC), Dr. Reddy's Laboratories Ltd (RDY), Bioverativ (BIVV), DexCom (DXCM) and Icon Plc (ICLR).
Who are Masimo Corporation's key executives?
Masimo Corporation's management team includes the folowing people:
- Joseph E. Kiani, Chairman of the Board, Chief Executive Officer
- Mark P. de Raad, Chief Financial Officer, Executive Vice President - Finance
- Jon Coleman, President - Worldwide Sales, Professional Services and Medical Affairs
- Rick Fishel, President - Worldwide OEM Business & Strategic Development
- Anand Sampath, Chief Operating Officer
- Yongsam Lee, Executive Vice President, Chief Information Officer
- Tom McClenahan, Executive Vice President, General Counsel, Corporate Secretary
- Steven J. Barker M.D., Ph.D., Director
- Sanford Fitch, Independent Director
- Thomas Harkin, Independent Director
Who owns Masimo Corporation stock?
Masimo Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.24%), Vanguard Group Inc. (9.50%), Acadian Asset Management LLC (3.50%), State Street Corp (2.98%), Arrowstreet Capital Limited Partnership (2.14%) and Robeco Institutional Asset Management B.V. (2.11%). Company insiders that own Masimo Corporation stock include Anand Sampath, Joe E Kiani, Jon Coleman, Paul Jansen, Raad Mark De, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo Corporation.
Who sold Masimo Corporation stock? Who is selling Masimo Corporation stock?
Masimo Corporation's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Numeric Investors LLC, Westfield Capital Management Co. LP, BTIM Corp., Goldman Sachs Group Inc., Canada Pension Plan Investment Board, Rothschild Asset Management Inc. and Schroder Investment Management Group. Company insiders that have sold Masimo Corporation stock in the last year include Anand Sampath, Joe E Kiani, Jon Coleman, Paul Jansen, Raad Mark De, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Thomas Samuel Mcclenahan and Yongsam Lee. View Insider Buying and Selling for Masimo Corporation.
Who bought Masimo Corporation stock? Who is buying Masimo Corporation stock?
Masimo Corporation's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Koch Industries Inc., Acadian Asset Management LLC, JPMorgan Chase & Co., Vanguard Group Inc., Capital Fund Management S.A., Robeco Institutional Asset Management B.V. and Russell Investments Group Ltd.. View Insider Buying and Selling for Masimo Corporation.
How do I buy Masimo Corporation stock?
Shares of Masimo Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Masimo Corporation's stock price today?
One share of Masimo Corporation stock can currently be purchased for approximately $84.98.
MarketBeat Community Rating for Masimo Corporation (NASDAQ MASI)MarketBeat's community ratings are surveys of what our community members think about Masimo Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Masimo Corporation (NASDAQ:MASI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.57) |
| Consensus Price Target: | $97.00 (14.14% upside) |
Analysts' Ratings History for Masimo Corporation (NASDAQ:MASI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/14/2017 | BTIG Research | Upgrade | Neutral -> Buy | $100.00 | Medium |  |
| 8/3/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $105.00 -> $108.00 | High | |
| 7/19/2017 | Roth Capital | Boost Price Target | Buy | $96.00 -> $105.00 | Low | |
| 5/22/2017 | Wedbush | Reiterated Rating | Outperform | $112.00 | Low | |
| 3/16/2017 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | High | |
| 2/13/2017 | Raymond James Financial, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
| 2/13/2017 | Citigroup Inc. | Downgrade | Market Perform | $60.00 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Masimo Corporation (NASDAQ:MASI)Earnings History by Quarter for Masimo Corporation (NASDAQ MASI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | | | | | | N/A | |
| 8/2/2017 | Q2 2017 | $0.71 | $0.83 | $189.03 million | $192.90 million | View | Listen | |
| 5/3/2017 | Q1 2017 | $0.60 | $0.82 | $184.14 million | $186.30 million | View | Listen | |
| 2/14/2017 | Q416 | $0.52 | $0.51 | $180.48 million | $183.20 million | View | Listen | |
| 11/2/2016 | Q316 | $0.42 | $0.52 | $165.51 million | $167.60 million | View | Listen | |
| 8/3/2016 | Q216 | $0.41 | $0.57 | $166.02 million | $172.64 million | View | Listen | |
| 5/4/2016 | Q116 | $0.43 | $0.53 | $165.25 million | $171.20 million | View | Listen | |
| 2/23/2016 | Q415 | $0.39 | $0.15 | $164.25 million | $167.30 million | View | Listen | |
| 11/5/2015 | Q315 | $0.31 | $0.36 | $149.31 million | $152.60 million | View | Listen | |
| 8/4/2015 | Q215 | $0.32 | $0.43 | $147.93 million | $155.73 million | View | Listen | |
| 5/6/2015 | Q115 | $0.35 | $0.41 | $151.00 million | $154.54 million | View | Listen | |
| 2/17/2015 | Q414 | $0.37 | $0.40 | $159.45 million | $161.80 million | View | Listen | |
| 10/29/2014 | Q314 | $0.25 | $0.27 | $144.20 million | $144.10 million | View | Listen | |
| 8/7/2014 | Q214 | $0.29 | $0.27 | $145.76 million | $140.92 million | View | Listen | |
| 4/30/2014 | Q114 | $0.29 | $0.39 | $144.01 million | $139.80 million | View | Listen | |
| 2/13/2014 | Q413 | $0.31 | $0.31 | $148.25 million | $134.70 million | View | Listen | |
| 10/30/2013 | Q313 | $0.26 | $0.27 | $132.47 million | $131.40 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.28 | $0.30 | $136.36 million | $137.42 million | View | Listen | |
| 5/2/2013 | Q1 2013 | $0.28 | $0.28 | $134.46 million | $135.90 million | View | Listen | |
| 2/14/2013 | Q4 2012 | $0.29 | $0.26 | $129.09 million | $132.20 million | View | Listen | |
| 11/1/2012 | Q312 | $0.26 | $0.26 | $120.99 million | $112.10 million | View | N/A | |
| 8/1/2012 | | $0.28 | $0.27 | | | View | N/A | |
| 5/2/2012 | | $0.28 | $0.27 | | | View | N/A | |
| 2/14/2012 | | $0.23 | $0.23 | | | View | N/A | |
| 10/25/2011 | | $0.27 | $0.24 | | | View | N/A | |
| 8/9/2011 | | $0.28 | $0.28 | | | View | N/A | |
| 5/3/2011 | | $0.30 | $0.30 | | | View | N/A | |
| 2/15/2011 | | $0.26 | $0.29 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Masimo Corporation (NASDAQ:MASI)2017 EPS Consensus Estimate: $2.30
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.59 | $0.60 | $0.60 |
| Q2 2017 | 2 | $0.54 | $0.55 | $0.55 |
| Q3 2017 | 2 | $0.53 | $0.53 | $0.53 |
| Q4 2017 | 2 | $0.62 | $0.64 | $0.63 |
(Data provided by Zacks Investment Research)
Dividend History for Masimo Corporation (NASDAQ:MASI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Masimo Corporation (NASDAQ:MASI)Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 83.21%
Insider Trades by Quarter for Masimo Corporation (NASDAQ:MASI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/17/2017 | Sanford Fitch | Director | Sell | 11,000 | $87.25 | $959,750.00 | |
| 7/20/2017 | Jon Coleman | Insider | Sell | 25,000 | $97.50 | $2,437,500.00 | |
| 7/14/2017 | Rick Fishel | Insider | Sell | 15,000 | $94.85 | $1,422,750.00 | |
| 7/13/2017 | Sanford Fitch | Director | Sell | 6,000 | $91.89 | $551,340.00 | |
| 7/11/2017 | Anand Sampath | COO | Sell | 40,000 | $92.00 | $3,680,000.00 | |
| 7/11/2017 | Rick Fishel | Insider | Sell | 15,000 | $92.85 | $1,392,750.00 | |
| 6/29/2017 | Sanford Fitch | Director | Sell | 14,000 | $92.06 | $1,288,840.00 | |
| 5/1/2017 | Joe E Kiani | CEO | Sell | 145,841 | $102.37 | $14,929,743.17 | |
| 4/28/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 8,000 | $102.75 | $822,000.00 | |
| 4/26/2017 | Joe E Kiani | CEO | Sell | 154,159 | $99.70 | $15,369,652.30 | |
| 4/25/2017 | Joe E Kiani | CEO | Sell | 13,201 | $101.00 | $1,333,301.00 | |
| 4/25/2017 | Jon Coleman | Insider | Sell | 50,000 | $100.00 | $5,000,000.00 | |
| 4/25/2017 | Yongsam Lee | EVP | Sell | 10,000 | $100.00 | $1,000,000.00 | |
| 4/24/2017 | Joe E Kiani | CEO | Sell | 100,000 | $99.00 | $9,900,000.00 | |
| 4/24/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $98.75 | $987,500.00 | |
| 4/20/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $95.75 | $957,500.00 | |
| 4/19/2017 | Yongsam Lee | EVP | Sell | 10,000 | $95.00 | $950,000.00 | |
| 4/4/2017 | Raad Mark De | CFO | Sell | 48,000 | $93.25 | $4,476,000.00 | |
| 3/22/2017 | Sanford Fitch | Director | Sell | 3,000 | $93.23 | $279,690.00 | |
| 3/10/2017 | Paul Jansen | EVP | Sell | 55,611 | $94.47 | $5,253,571.17 | |
| 3/9/2017 | Ramshorst David J Van | Insider | Sell | 7,500 | $94.20 | $706,500.00 | |
| 2/23/2017 | Raad Mark De | CFO | Sell | 30,000 | $86.25 | $2,587,500.00 | |
| 2/17/2017 | Raad Mark De | CFO | Sell | 45,000 | $80.00 | $3,600,000.00 | |
| 2/16/2017 | Joe E Kiani | CEO | Sell | 300,000 | $80.04 | $24,012,000.00 | |
| 2/3/2017 | Jon Coleman | Insider | Sell | 6,000 | $75.00 | $450,000.00 | |
| 2/3/2017 | Raad Mark De | CFO | Sell | 15,000 | $75.00 | $1,125,000.00 | |
| 1/27/2017 | Jon Coleman | Insider | Sell | 5,800 | $72.50 | $420,500.00 | |
| 1/27/2017 | Raad Mark De | CFO | Sell | 15,000 | $72.50 | $1,087,500.00 | |
| 1/20/2017 | Jon Coleman | Insider | Sell | 200 | $72.50 | $14,500.00 | |
| 1/13/2017 | Yongsam Lee | EVP | Sell | 10,000 | $72.00 | $720,000.00 | |
| 1/10/2017 | Jon Coleman | Insider | Sell | 6,000 | $70.00 | $420,000.00 | |
| 1/10/2017 | Raad Mark De | CFO | Sell | 15,000 | $70.00 | $1,050,000.00 | |
| 1/10/2017 | Yongsam Lee | EVP | Sell | 10,000 | $70.00 | $700,000.00 | |
| 1/9/2017 | Paul Jansen | EVP | Sell | 17,945 | $68.88 | $1,236,051.60 | |
| 1/3/2017 | Ramshorst David J Van | Insider | Sell | 4,000 | $67.20 | $268,800.00 | |
| 12/27/2016 | Paul Jansen | EVP | Sell | 2,055 | $68.88 | $141,548.40 | |
| 12/21/2016 | Jon Coleman | Insider | Sell | 4,000 | $67.50 | $270,000.00 | |
| 12/16/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $66.00 | $660,000.00 | |
| 12/8/2016 | Paul Jansen | EVP | Sell | 10,000 | $63.88 | $638,800.00 | |
| 12/7/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 2,293 | $63.00 | $144,459.00 | |
| 12/6/2016 | Joe E Kiani | CEO | Sell | 52,859 | $62.03 | $3,278,843.77 | |
| 12/6/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 4,000 | $63.00 | $252,000.00 | |
| 12/1/2016 | Joe E Kiani | CEO | Sell | 36,119 | $62.06 | $2,241,545.14 | |
| 11/29/2016 | Joe E Kiani | CEO | Sell | 104,870 | $62.27 | $6,530,254.90 | |
| 11/23/2016 | Joe E Kiani | CEO | Sell | 85,771 | $62.06 | $5,322,948.26 | |
| 11/22/2016 | Joe E Kiani | CEO | Sell | 869 | $62.00 | $53,878.00 | |
| 11/21/2016 | Joe E Kiani | CEO | Sell | 30,462 | $62.04 | $1,889,862.48 | |
| 11/18/2016 | Joe E Kiani | CEO | Sell | 20,381 | $62.02 | $1,264,029.62 | |
| 11/1/2016 | Anand Sampath | COO | Sell | 65,000 | $55.04 | $3,577,600.00 | |
| 10/31/2016 | Anand Sampath | COO | Sell | 51,345 | $55.05 | $2,826,542.25 | |
| 10/19/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.05 | $118,100.00 | |
| 10/10/2016 | Joe E Kiani | CEO | Sell | 84,617 | $60.26 | $5,099,020.42 | |
| 10/10/2016 | Yongsam Lee | EVP | Sell | 30,000 | $60.50 | $1,815,000.00 | |
| 10/5/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.58 | $119,160.00 | |
| 10/4/2016 | Joe E Kiani | CEO | Sell | 4,300 | $60.07 | $258,301.00 | |
| 10/3/2016 | Joe E Kiani | CEO | Sell | 2,200 | $60.00 | $132,000.00 | |
| 9/30/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $59.00 | $590,000.00 | |
| 9/27/2016 | Joe E Kiani | CEO | Sell | 4,464 | $60.01 | $267,884.64 | |
| 9/22/2016 | Joe E Kiani | CEO | Sell | 49,484 | $60.18 | $2,977,947.12 | |
| 9/21/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.41 | $118,820.00 | |
| 9/20/2016 | Joe E Kiani | CEO | Sell | 400 | $60.16 | $24,064.00 | |
| 9/19/2016 | Joe E Kiani | CEO | Sell | 999 | $60.03 | $59,969.97 | |
| 9/7/2016 | Joe E Kiani | CEO | Sell | 33,536 | $60.00 | $2,012,160.00 | |
| 9/7/2016 | Jon Coleman | Insider | Sell | 6,000 | $60.00 | $360,000.00 | |
| 9/7/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.81 | $119,620.00 | |
| 8/17/2016 | Sanford Fitch | Director | Sell | 2,000 | $58.11 | $116,220.00 | |
| 8/4/2016 | Jon Coleman | Insider | Sell | 22,000 | $56.82 | $1,250,040.00 | |
| 8/4/2016 | Paul Jansen | EVP | Sell | 10,000 | $58.88 | $588,800.00 | |
| 8/3/2016 | Sanford Fitch | Director | Sell | 2,000 | $52.62 | $105,240.00 | |
| 7/20/2016 | Rick Fishel | Insider | Sell | 22,000 | $53.85 | $1,184,700.00 | |
| 7/20/2016 | Sanford Fitch | Director | Sell | 3,000 | $53.48 | $160,440.00 | |
| 6/30/2016 | Ramshorst David J Van | CAO | Sell | 5,000 | $52.50 | $262,500.00 | |
| 6/7/2016 | Joe E Kiani | CEO | Sell | 65,048 | $50.00 | $3,252,400.00 | |
| 6/3/2016 | Joe E Kiani | CEO | Sell | 234,952 | $50.09 | $11,768,745.68 | |
| 6/1/2016 | Jon Coleman | Insider | Sell | 4,000 | $50.00 | $200,000.00 | |
| 5/31/2016 | Raad Mark De | CFO | Sell | 40,000 | $49.43 | $1,977,200.00 | |
| 5/25/2016 | Rick Fishel | Insider | Sell | 25,000 | $49.85 | $1,246,250.00 | |
| 5/5/2016 | Jon Coleman | Insider | Sell | 8,000 | $47.00 | $376,000.00 | |
| 4/28/2016 | Paul Jansen | EVP | Sell | 10,000 | $44.88 | $448,800.00 | |
| 4/27/2016 | Jon Coleman | Insider | Sell | 4,000 | $44.00 | $176,000.00 | |
| 3/23/2016 | Yongsam Lee | EVP | Sell | 96,000 | $39.96 | $3,836,160.00 | |
| 3/22/2016 | Yongsam Lee | EVP | Sell | 32,000 | $40.06 | $1,281,920.00 | |
| 3/21/2016 | Yongsam Lee | EVP | Sell | 32,000 | $39.83 | $1,274,560.00 | |
| 3/15/2016 | Raad Mark De | CFO | Sell | 40,000 | $39.00 | $1,560,000.00 | |
| 2/29/2016 | Raad Mark De | CFO | Sell | 40,000 | $38.11 | $1,524,400.00 | |
| 12/24/2015 | Jon Coleman | insider | Sell | 10,000 | $42.00 | $420,000.00 | |
| 12/9/2015 | Sanford Fitch | Director | Sell | 2,000 | $41.00 | $82,000.00 | |
| 11/11/2015 | Sanford Fitch | Director | Sell | 2,000 | $42.67 | $85,340.00 | |
| 11/6/2015 | Anand Sampath | COO | Sell | 45,000 | $42.00 | $1,890,000.00 | |
| 11/6/2015 | Jon Coleman | insider | Sell | 10,000 | $42.38 | $423,800.00 | |
| 10/14/2015 | Sanford Fitch | Director | Sell | 2,000 | $39.29 | $78,580.00 | |
| 9/17/2015 | Paul Jansen | EVP | Sell | 10,000 | $42.88 | $428,800.00 | |
| 9/9/2015 | Sanford Fitch | Director | Sell | 2,000 | $41.29 | $82,580.00 | |
| 8/31/2015 | Thomas Samuel Mcclenahan | EVP | Sell | 22,000 | $40.62 | $893,640.00 | |
| 8/26/2015 | Paul Jansen | EVP | Sell | 10,000 | $40.88 | $408,800.00 | |
| 7/22/2015 | Rick Fishel | Insider | Sell | 35,084 | $41.85 | $1,468,265.40 | |
| 7/21/2015 | Joe E Kiani | CEO | Sell | 300,000 | $40.55 | $12,165,000.00 | |
| 7/21/2015 | Steven Barker | Director | Sell | 20,000 | $40.00 | $800,000.00 | |
| 7/8/2015 | Sanford Fitch | Director | Sell | 2,000 | $38.18 | $76,360.00 | |
| 6/10/2015 | Sanford Fitch | Director | Sell | 2,000 | $36.49 | $72,980.00 | |
| 6/4/2015 | Steven Barker | Director | Sell | 25,000 | $36.20 | $905,000.00 | |
| 4/8/2015 | Sanford Fitch | Director | Sell | 2,000 | $34.57 | $69,140.00 | |
| 2/18/2015 | Rick Fishel | Insider | Sell | 18,170 | $29.85 | $542,374.50 | |
| 5/22/2013 | Robert Coleman | Director | Sell | 59,400 | $21.93 | $1,302,642.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Masimo Corporation (NASDAQ:MASI)
Latest Headlines for Masimo Corporation (NASDAQ:MASI)
| Source: |
|
| Date | Headline |
|---|
 | Global Pulse Oximeter Market Will Reach USD 2393.3 Million by 2022: Zion Market Research
www.marketwatch.com - September 22 at 9:25 AM |
 | The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
finance.yahoo.com - September 22 at 9:25 AM |
| Here's Why Investors Should Buy Masimo (MASI) Right Now
finance.yahoo.com - September 22 at 9:25 AM |
 | Medical Equipment Stocks on Investors' Radar -- Align Technology, Masimo, Corindus Vascular Robotics, and Avinger - PR Newswire (press release)
www.prnewswire.com - September 21 at 5:37 PM |
| Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy - Yahoo News
finance.yahoo.com - September 21 at 5:37 PM |
 | Masimo Corporation (MASI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 20 at 4:44 AM |
 | Masimo Corp. (MASI) Reports FDA Clearance and Full Market Release of Rad-97 Pulse CO-Oximeter
www.streetinsider.com - September 19 at 1:36 AM |
| Masimo Corporation (MASI) Expected to Announce Quarterly Sales of $188.62 Million
www.americanbankingnews.com - September 19 at 1:16 AM |
| Masimo Corp. (MASI) Reports FDA Clearance and Full Market ... - StreetInsider.com
www.streetinsider.com - September 18 at 8:13 PM |
| Masimo Announces FDA Clearance and Full Market Release of Rad-97™ Pulse CO-Oximeter®
finance.yahoo.com - September 18 at 8:13 PM |
| Masimo gets FDA clearance for its patient monitoring system
finance.yahoo.com - September 18 at 8:13 PM |
| Masimo Corporation (MASI) Expected to Announce Earnings of $0.53 Per Share
www.americanbankingnews.com - September 17 at 10:30 PM |
| Newborn Foundation and Masimo Partnership Reaches 52,000 Babies and 1,000 Health Workers through Newborn Screening Initiative in Support of Every Woman Every Child
finance.yahoo.com - September 15 at 6:18 AM |
 | Masimo Corporation Fell 12.7% in August -- but Why?
www.fool.com - September 11 at 6:07 PM |
 | Why Is Masimo (MASI) Down 1.5% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - September 8 at 2:56 AM |
| Why Is Masimo (MASI) Down 1.5% Since the Last Earnings Report?
finance.yahoo.com - September 7 at 12:56 AM |
| Masimo to Present at 15th Annual Morgan Stanley Global Healthcare Conference
finance.yahoo.com - September 7 at 12:56 AM |
| Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks - Nasdaq
www.nasdaq.com - September 5 at 9:26 PM |
| Study Evaluates Performance of Masimo iSpO2® Rx Smart Device-Paired Pulse Oximeter in Screening Newborns for Critical Congenital Heart Disease
finance.yahoo.com - September 5 at 5:25 AM |
| $188.62 Million in Sales Expected for Masimo Corporation (MASI) This Quarter
www.americanbankingnews.com - September 1 at 6:04 AM |
| Masimo Breaks Above 200-Day Moving Average - Bullish for MASI ... - Nasdaq
www.nasdaq.com - September 1 at 3:30 AM |
 | Study Evaluates Utility of Masimo SpHb During High-Blood-Loss Oncosurgery
www.finanznachrichten.de - August 28 at 5:32 AM |
| Study Evaluates Utility of Masimo SpHb® During High-Blood-Loss Oncosurgery
finance.yahoo.com - August 28 at 5:32 AM |
 | Here's Why Masimo (MASI) is a Suitable Value Pick for Now
www.zacks.com - August 26 at 7:52 PM |
 | BRIEF-Masimo says CFO Mark De Raad to retire
www.reuters.com - August 26 at 6:56 AM |
| Masimo Corporation (MASI) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - August 26 at 4:34 AM |
| BRIEF-Masimo says CFO Mark De Raad to retire - Reuters
www.reuters.com - August 25 at 8:10 AM |
| Here's Why Masimo (MASI) is a Suitable Value Pick for Now - Nasdaq
www.nasdaq.com - August 25 at 8:10 AM |
| Masimo Corporation (MASI) vs. Entellus Medical (ENTL) Head to Head Survey
www.americanbankingnews.com - August 22 at 2:22 PM |
| Study Investigates Performance of Masimo PVi As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery
www.finanznachrichten.de - August 21 at 7:46 PM |
| Sanford Fitch Sells 11,000 Shares of Masimo Corporation (MASI) Stock
www.americanbankingnews.com - August 21 at 7:26 PM |
| Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery
finance.yahoo.com - August 21 at 8:14 AM |
| Reviewing Masimo Corporation (MASI) and Entellus Medical (ENTL)
www.americanbankingnews.com - August 18 at 4:22 PM |
| Masimo Corp. – Value Analysis (NASDAQ:MASI) : August 17, 2017
finance.yahoo.com - August 17 at 1:44 AM |
| Dubai Health Authority Implements Masimo Patient SafetyNet™
finance.yahoo.com - August 14 at 12:04 AM |
| Financial Review: Entellus Medical (ENTL) and Masimo Corporation (NASDAQ:MASI)
www.americanbankingnews.com - August 13 at 9:00 AM |
 | MASI Beat Estimates, Then Dropped Like A Rock
seekingalpha.com - August 12 at 3:59 AM |
| Masimo Corporation (MASI) & Entellus Medical (ENTL) Financial Comparison
www.americanbankingnews.com - August 12 at 12:30 AM |
| Masimo (MASI) Shares Cross Below 200 DMA
www.nasdaq.com - August 11 at 6:22 AM |
| See what the IHS Markit Score report has to say about Masimo Corp.
finance.yahoo.com - August 10 at 4:32 AM |
| Wedbush Weighs in on Masimo Corporation's Q3 2017 Earnings (MASI)
www.americanbankingnews.com - August 7 at 7:40 AM |
| Study Evaluates Performance of Masimo SpHb® in Trauma Patients with Low Hemoglobin Levels
finance.yahoo.com - August 7 at 5:03 AM |
| Down 9.8%: Is Masimo Corporation Stock a Contrarian Buy? - Motley Fool
www.fool.com - August 5 at 2:26 AM |
| Masimo Corp. breached its 50 day moving average in a Bearish Manner : MASI-US : August 4, 2017
finance.yahoo.com - August 5 at 2:26 AM |
| Edited Transcript of MASI earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 5 at 2:26 AM |
| Masimo Corporation to Post FY2017 Earnings of $2.80 Per Share, William Blair Forecasts (MASI)
www.americanbankingnews.com - August 4 at 10:46 AM |
| Masimo Corporation Expected to Post FY2017 Earnings of $2.80 Per Share (NASDAQ:MASI)
www.americanbankingnews.com - August 4 at 10:46 AM |
| Down 9.8%: Is Masimo Corporation Stock a Contrarian Buy?
www.fool.com - August 4 at 9:20 AM |
| Masimo Corporation Raises Full-Year Guidance After Second-Quarter Earnings Soar - Motley Fool
www.fool.com - August 4 at 1:13 AM |
| Masimo Corporation (NASDAQ:MASI) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - August 3 at 10:28 PM |
Masimo Corporation (MASI) Chart for Friday, September, 22, 2017
